Enrollment Completed in Ph 2 I-SPY 2 Arm Evaluating Lasofoxifene in Neoadjuvant Breast Cancer Setting

“Sermonix is delighted to have quickly completed enrollment of this I-SPY 2 EOP study of lasofoxifene as a neoadjuvant endocrine therapy, complementing our ongoing ELAINE-3 Phase 3 combination study of lasofoxifene with abemaciclib in the ESR1-mutated metastatic breast cancer setting,” said Dr. David Portman, Sermonix founder and chief executive officer. “With a recent preclinical study also suggesting lasofoxifene could be an effective therapy for all hormone treatment-resistant breast tumors, and other data suggesting beneficial effects of lasofoxifene on genitourinary syndrome of menopause and bone health, we are focused on exploring the drug’s broad potential as a therapy for people confronted with breast cancer – and one that does so while potentially offering unique quality of life benefits across the treatment continuum.”